Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,000,000 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof), one […]
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, US – MAINZ, Germany – May 16, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company […]
Mainz Biomed Enters into Technology Partnership with EDX Medical Group

BERKELEY, US and MAINZ, Germany – April 29, 2025 – Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized […]
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

BERKELEY, US – MAINZ, Germany – April 28, 2025 — Mainz Biomed N.V. (NASDAQ: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first quarter of 2025, and provided an outlook on its path to FDA premarket approval. During the […]
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus Strategic partnerships with industry leaders mark key progress Company highlights its early accomplishments for 2025 BERKELEY, US – MAINZ, […]
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report Top-Line Results in Fourth Quarter 2025 BERKELEY, US – MAINZ, Germany – March 27, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular […]
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed Enters into Exclusive Licensing Agreement for the Portfolio of mRNA Biomarkers, with Continued Development of Machine Learning AI-Based Algorithm Based on Liquid Biosciences EMERGE Platform BERKELEY, US – MAINZ, Germany – March 13, […]
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

BERKELEY, US and MAINZ, Germany – March 3, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is proud to support Colorectal Cancer Awareness Month in March. Detecting colorectal cancer (CRC) in its early stages significantly improves survival rates, making awareness […]
Mainz Biomed Expands into Switzerland with labor team w

Partnership to Launch DNA-Based Colorectal Cancer Screening Test BERKELEY, US – MAINZ, Germany – February 20, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with labor team w ag (“labor team”), a renowned diagnostic laboratory […]
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Updated Screening Guidelines Ensure Broader Access to Colorectal Cancer Screening in Germany BERKELEY, US and MAINZ, Germany – February 11, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to share that its partner, GANZIMMUN Diagnostics, has officially launched […]